Bank of America Lowers Kura Oncology (NASDAQ:KURA) Price Target to $29.00

Kura Oncology (NASDAQ:KURA) had its target price trimmed by Bank of America from $36.00 to $29.00 in a report released on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities analysts also recently weighed in on KURA. HC Wainwright increased their price target on shares of Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday. UBS Group began coverage on shares of Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target on the stock. Jefferies Financial Group cut their price target on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Thursday. Finally, Wedbush reiterated an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $29.38.

Kura Oncology Price Performance

Shares of NASDAQ:KURA opened at $10.80 on Friday. Kura Oncology has a twelve month low of $9.06 and a twelve month high of $24.17. The company’s 50 day moving average is $18.08 and its 200 day moving average is $19.76. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market cap of $839.85 million, a PE ratio of -4.66 and a beta of 0.86.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Assenagon Asset Management S.A. lifted its position in shares of Kura Oncology by 50.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after buying an additional 577,732 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after purchasing an additional 28,212 shares in the last quarter. Sofinnova Investments Inc. lifted its holdings in Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after purchasing an additional 323,303 shares in the last quarter. Armistice Capital LLC lifted its holdings in Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after purchasing an additional 302,000 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Kura Oncology in the 1st quarter valued at $110,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.